Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
第一作者:
L,Collet
第一单位:
Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Brussels, Belgium; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; GINECO/GINEGEPS Group, Saint-Herblain, France. Electronic address: Laetitia.collet@hubruxelles.be.
作者:
医学主题词
人类(Humans);女(雌)性(Female);卵巢肿瘤(Ovarian Neoplasms);预后(Prognosis);中年人(Middle Aged);老年人(Aged);免疫疗法(Immunotherapy);肿瘤微环境(Tumor Microenvironment);成年人(Adult);间质细胞(Stromal Cells)
DOI
10.1016/j.esmoop.2025.105104
PMID
40472658
发布时间
2025-07-07
- 浏览0
ESMO open
2025年10卷6期
105104页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



